27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's (NASDAQ:ALDX) ADX-2191 to treat retinitis pigmentosa (RP).
- ADX-2191 is a methotrexate for intravitreal injection.
- Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation.
- Price Action: ALDX shares are up 0.56% at $9 during the market session on the last check Wednesday.
- Related content: Benzinga's Full FDA Calendar.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!